Halozyme Therapeutics, Inc. (HALO)

$39.44

+0.47

(+1.21%)▲

Live

Insights on Halozyme Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 216.03M → 230.03M (in $), with an average increase of 6.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, 39.61M → 85.38M (in $), with an average increase of 19.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 34.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 270.2%

Performance

  • $38.82
    $39.69
    $39.44
    downward going graph

    1.57%

    Downside

    Day's Volatility :2.19%

    Upside

    0.63%

    downward going graph
  • $29.85
    $45.00
    $39.44
    downward going graph

    24.32%

    Downside

    52 Weeks Volatility :33.67%

    Upside

    12.36%

    downward going graph

Returns

PeriodHalozyme Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
11.18%
1.9%
0.0%
6 Months
11.82%
10.7%
0.0%
1 Year
16.19%
4.6%
-1.1%
3 Years
-22.8%
14.2%
-22.1%

Highlights

Market Capitalization
4.9B
Book Value
$0.66
Earnings Per Share (EPS)
2.1
PE Ratio
18.43
PEG Ratio
-2.5
Wall Street Target Price
51.11
Profit Margin
33.96%
Operating Margin TTM
45.01%
Return On Assets TTM
11.89%
Return On Equity TTM
222.07%
Revenue TTM
829.3M
Revenue Per Share TTM
6.29
Quarterly Revenue Growth YOY
26.700000000000003%
Gross Profit TTM
454.2M
EBITDA
416.9M
Diluted Eps TTM
2.1
Quarterly Earnings Growth YOY
0.55
EPS Estimate Current Year
3.69
EPS Estimate Next Year
4.56
EPS Estimate Current Quarter
0.82
EPS Estimate Next Quarter
0.87

Analyst Recommendation

Buy
    77%Buy
    16%Hold
    5%Sell
Based on 18 Wall street analysts offering stock ratings for Halozyme Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
13
Hold
3
3
3
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 29.59%

Current $39.44
Target $51.11

Company Financials

FY18Y/Y Change
Revenue
151.9M
↓ 52.04%
Net Income
-80.3M
↓ 227.57%
Net Profit Margin
-52.9%
↓ 72.79%
FY19Y/Y Change
Revenue
196.0M
↑ 29.06%
Net Income
-72.2M
↓ 10.07%
Net Profit Margin
-36.86%
↑ 16.04%
FY20Y/Y Change
Revenue
267.6M
↑ 36.53%
Net Income
129.1M
↓ 278.69%
Net Profit Margin
48.24%
↑ 85.1%
FY21Y/Y Change
Revenue
443.3M
↑ 65.67%
Net Income
402.7M
↑ 211.97%
Net Profit Margin
90.84%
↑ 42.6%
FY22Y/Y Change
Revenue
660.1M
↑ 48.91%
Net Income
202.1M
↓ 49.81%
Net Profit Margin
30.62%
↓ 60.22%
FY23Y/Y Change
Revenue
829.3M
↑ 25.62%
Net Income
281.6M
↑ 39.31%
Net Profit Margin
33.96%
↑ 3.34%
Q3 FY22Q/Q Change
Revenue
209.0M
↑ 37.15%
Net Income
61.6M
↑ 171.69%
Net Profit Margin
29.49%
↑ 14.6%
Q4 FY22Q/Q Change
Revenue
181.5M
↓ 13.15%
Net Income
57.7M
↓ 6.38%
Net Profit Margin
31.79%
↑ 2.3%
Q1 FY23Q/Q Change
Revenue
162.1M
↓ 10.66%
Net Income
39.6M
↓ 31.35%
Net Profit Margin
24.43%
↓ 7.36%
Q2 FY23Q/Q Change
Revenue
221.0M
↑ 36.32%
Net Income
74.8M
↑ 88.7%
Net Profit Margin
33.82%
↑ 9.39%
Q3 FY23Q/Q Change
Revenue
216.0M
↓ 2.26%
Net Income
81.8M
↑ 9.48%
Net Profit Margin
37.88%
↑ 4.06%
Q4 FY23Q/Q Change
Revenue
230.0M
↑ 6.48%
Net Income
85.4M
↑ 4.34%
Net Profit Margin
37.12%
↓ 0.76%
FY18Y/Y Change
Total Assets
440.2M
↓ 15.33%
Total Liabilities
191.4M
↓ 38.58%
FY19Y/Y Change
Total Assets
565.9M
↑ 28.54%
Total Liabilities
474.1M
↑ 147.76%
FY20Y/Y Change
Total Assets
579.9M
↑ 2.48%
Total Liabilities
428.9M
↓ 9.54%
FY21Y/Y Change
Total Assets
1.1B
↑ 90.44%
Total Liabilities
907.5M
↑ 111.59%
FY22Y/Y Change
Total Assets
1.8B
↑ 66.74%
Total Liabilities
1.7B
↑ 84.22%
FY23Y/Y Change
Total Assets
1.7B
↓ 5.88%
Total Liabilities
1.6B
↓ 1.33%
Q3 FY22Q/Q Change
Total Assets
1.9B
↑ 4.67%
Total Liabilities
1.8B
↑ 18.77%
Q4 FY22Q/Q Change
Total Assets
1.8B
↓ 1.24%
Total Liabilities
1.7B
↓ 5.42%
Q1 FY23Q/Q Change
Total Assets
1.7B
↓ 7.71%
Total Liabilities
1.6B
↓ 2.28%
Q2 FY23Q/Q Change
Total Assets
1.8B
↑ 6.53%
Total Liabilities
1.7B
↑ 1.58%
Q3 FY23Q/Q Change
Total Assets
1.9B
↑ 4.54%
Total Liabilities
1.6B
↓ 0.96%
Q4 FY23Q/Q Change
Total Assets
1.7B
↓ 8.42%
Total Liabilities
1.6B
↑ 0.36%
FY18Y/Y Change
Operating Cash Flow
-49.5M
↓ 136.93%
Investing Cash Flow
2.5M
↓ 101.52%
Financing Cash Flow
-63.8M
↓ 148.46%
FY19Y/Y Change
Operating Cash Flow
-85.4M
↑ 72.57%
Investing Cash Flow
-5.5M
↓ 322.58%
Financing Cash Flow
153.2M
↓ 340.16%
FY20Y/Y Change
Operating Cash Flow
55.5M
↓ 164.92%
Investing Cash Flow
78.4M
↓ 1512.04%
Financing Cash Flow
-106.3M
↓ 169.37%
FY21Y/Y Change
Operating Cash Flow
299.4M
↑ 439.98%
Investing Cash Flow
-406.3M
↓ 618.53%
Financing Cash Flow
77.9M
↓ 173.26%
FY22Y/Y Change
Operating Cash Flow
240.1M
↓ 19.81%
Investing Cash Flow
-487.0M
↑ 19.87%
Financing Cash Flow
362.4M
↑ 365.38%
Q3 FY22Q/Q Change
Operating Cash Flow
69.6M
↑ 73.11%
Investing Cash Flow
-1.0M
↓ 99.77%
Financing Cash Flow
-12.4M
↓ 103.37%
Q4 FY22Q/Q Change
Operating Cash Flow
82.5M
↑ 18.41%
Investing Cash Flow
-1.7M
↑ 73.21%
Financing Cash Flow
6.3M
↓ 151.04%
Q1 FY23Q/Q Change
Operating Cash Flow
87.0M
↑ 5.47%
Investing Cash Flow
-60.2M
↑ 3345.7%
Financing Cash Flow
-164.6M
↓ 2700.95%
Q2 FY23Q/Q Change
Operating Cash Flow
66.8M
↓ 23.14%
Investing Cash Flow
55.0M
↓ 191.41%
Financing Cash Flow
2.4M
↓ 101.49%
Q3 FY23Q/Q Change
Operating Cash Flow
132.4M
↑ 98.1%
Investing Cash Flow
-83.5M
↓ 251.74%
Financing Cash Flow
4.1M
↑ 67.66%

Technicals Summary

Sell

Neutral

Buy

Halozyme Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.
-3.59%
11.82%
16.19%
-22.8%
141.0%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.
18.43
18.43
-2.5
3.69
2.22
0.12
NA
0.66
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.
Buy
$4.9B
141.0%
18.43
33.96%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    14.66%

  • Vanguard Group Inc

    10.44%

  • Artisan Partners Limited Partnership

    5.26%

  • State Street Corporation

    5.10%

  • Snyder Capital Management LP

    2.92%

  • AllianceBernstein L.P.

    2.73%

Company Information

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies

Organization
Halozyme Therapeutics, Inc.
Employees
373
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Industry
Health Technology

Discover More

FAQs